Literature DB >> 12855330

The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin.

Rui-Qing Sun1, Nada B Lawand, William D Willis.   

Abstract

This study was designed to assess the role of calcitonin gene-related peptide (CGRP) and its receptor in the generation and maintenance of secondary mechanical allodynia and hyperalgesia induced by intradermal injection of capsaicin in rats. Paw withdrawal responses (PWRs) to von Frey hairs with different bending forces applied on the rat paw were tested in this study. CGRP(8-37), a specific antagonist of CGRP 1 receptors, was delivered through a microdialysis fiber inserted across the dorsal horn. Post- and pretreatment paradigms were followed. When CGRP(8-37) was administered 1h after capsaicin injection, the mechanical allodynia and hyperalgesia were partially reversed in a dose-dependent manner. On the other hand, when rats were treated with CGRP(8-37) prior to capsaicin injection, the PWRs to von Frey applications were significantly reduced as compared to control animals. Collectively, these results suggest that CGRP receptors present in the dorsal horn are involved in the generation and maintenance of nociceptive behaviors associated with cutaneous inflammation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12855330     DOI: 10.1016/s0304-3959(03)00008-3

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  36 in total

1.  Distribution and injury-induced plasticity of cadherins in relationship to identified synaptic circuitry in adult rat spinal cord.

Authors:  John H Brock; Alice Elste; George W Huntley
Journal:  J Neurosci       Date:  2004-10-06       Impact factor: 6.167

Review 2.  Locomotor dysfunction and pain: the scylla and charybdis of fiber sprouting after spinal cord injury.

Authors:  Ronald Deumens; Elbert A J Joosten; Stephen G Waxman; Bryan C Hains
Journal:  Mol Neurobiol       Date:  2008-04-15       Impact factor: 5.590

Review 3.  Unravelling the mystery of capsaicin: a tool to understand and treat pain.

Authors:  Jessica O'Neill; Christina Brock; Anne Estrup Olesen; Trine Andresen; Matias Nilsson; Anthony H Dickenson
Journal:  Pharmacol Rev       Date:  2012-10       Impact factor: 25.468

4.  Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine.

Authors:  Paul L Durham; Carrie V Vause
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

Review 5.  CGRP receptor antagonism and migraine.

Authors:  Lars Edvinsson; Tony W Ho
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

6.  Repression of calcitonin gene-related peptide expression in trigeminal neurons by a Theobroma cacao extract.

Authors:  Marcie J Abbey; Vinit V Patil; Carrie V Vause; Paul L Durham
Journal:  J Ethnopharmacol       Date:  2007-10-05       Impact factor: 4.360

Review 7.  Cerebral hemodynamics in the different phases of migraine and cluster headache.

Authors:  Jakob M Hansen; Christoph J Schankin
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-31       Impact factor: 6.200

8.  Genetic enhancement of calcitonin gene-related Peptide-induced central sensitization to mechanical stimuli in mice.

Authors:  Blanca Marquez de Prado; Donna L Hammond; Andrew F Russo
Journal:  J Pain       Date:  2009-07-22       Impact factor: 5.820

Review 9.  Central sensitization: a generator of pain hypersensitivity by central neural plasticity.

Authors:  Alban Latremoliere; Clifford J Woolf
Journal:  J Pain       Date:  2009-09       Impact factor: 5.820

10.  Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.

Authors:  Theodore J Price; Amol Patwardhan; Armen N Akopian; Kenneth M Hargreaves; Christopher M Flores
Journal:  Br J Pharmacol       Date:  2004-03-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.